Research Topics
| Marcus LindSummaryCountry: Sweden Publications
| Collaborators
|
Detail Information
Publications
The effect of insulin lispro on glycemic control in a large patient cohortMarcus Lind
Department of Medicine, Uddevalla Hospital, Sweden
Diabetes Technol Ther 11:51-6. 2009..We therefore studied how glycemic control has been affected by using insulin lispro in clinical practice over 5 years in 14 hospitals in Sweden...- Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillationMarcus Lind
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Thromb Res 129:32-5. 2012..CONCLUSIONS: The SDT(INR) is a better predictor of mortality, stroke, bleeding and hospitalisation than the TTR in patients with atrial fibrillation receiving warfarin therapy... - Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfactionMarcus Lind
Department of Molecular and Clinical Medicine, Institute of Medicine Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Prim Care Diabetes 6:41-6. 2012..To evaluate the effects of adding glucagon-like peptide-1 (GLP-1) analogue therapy to insulin on glycated hemoglobin (HbA1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia... - The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetesMarcus Lind
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Prim Care Diabetes 6:53-9. 2012..To elucidate methodological questions in assessing the relationship between insulin treatment and cancer, since the risk of tumour growth generally increases with longer exposure time and higher dose of a growth promoting substance... - The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variablesMarcus Lind
Department of Medicine, Uddevalla Hospital, Uddevalla, Sweden
PLoS ONE 4:e4412. 2009..We studied whether the updated mean HbA1c underestimated the risk of diabetic complications... - The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effectsM Lind
Department of Medicine, NU Hospital Organization, SE 451 80 Uddevalla, Sweden
Diabetologia 53:1093-8. 2010..We determined the shape of the metabolic memory of HbA1c and its contribution to retinopathy, as well as the importance of reducing HbA1c to prevent progression of retinopathy... - Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational studyMarcus Lind
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Lancet 378:140-6. 2011..We aimed to assess this association in a large cohort of patients with type 1 diabetes identified from the Swedish national diabetes registry... - Thrombomodulin as a marker for bleeding complications during warfarin treatmentMarcus Lind
Department of Medicine, Skellefteå County Hospital, Skellefteå, Sweden
Arch Intern Med 169:1210-5. 2009..This study aimed to test if thrombomodulin (TM) concentrations were associated with bleeding complications, cardiovascular events, or mortality in long-term anticoagulant-treated patients... - Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practiceJenny Anderson
Department of Medicine, NU Hospital Organization, Trollhattan, Sweden
J Diabetes Sci Technol 5:1472-9. 2011..The effects of CGM on glycemic control in clinical practice in relation to indication and duration of use has not been completely studied...